The answer begins with meticulous control of hematocrit, spot volume, and sample homogeneity. When developing a validated Dried Blood Spot (DBS) assay, you must wrestle with the unique properties of whole blood—how it spreads, how it dries, and how you introduce your internal standard. Capillary plasma microsampling addresses the most stubborn of these variables by converting whole blood into dried plasma spots (DPS), which eliminates the hematocrit-driven matrix effects that plague traditional DBS.
DBS validation hinges on controlling variables introduced by whole-blood sampling: hematocrit concentration, spot volume, internal standard application, and sub-punch homogeneity. Capillary microsampling bypasses these issues by pre-separating plasma via centrifugation within the collection device, producing a dried plasma spot that retains the logistical benefits of DBS without its whole-blood interferences.
The Unique Analytical Challenges of Dried Blood Spot Assays
DBS offers a simple, low-volume sampling platform, but that simplicity masks a complex matrix. Validating a robust assay means confronting preanalytical variables that alter analyte distribution and recovery.
Hematocrit: The Primary Source of Bias
Hematocrit concentration directly changes blood viscosity, which in turn affects how the blood spot spreads and dries. A higher hematocrit produces a smaller, thicker spot for the same applied volume, while a lower hematocrit yields a larger, thinner spot.
This area bias means that if you take a fixed-diameter sub-punch from spots with different hematocrits, you will sample unequal volumes of blood. Your quantitation becomes hematocrit-dependent, introducing a systematic error that is difficult to correct unless you know the hematocrit of every sample.
Spot Volume and Drying Homogeneity
The volume of blood applied to the card is not always consistent in field settings. Variability in applied volume alters spot size, drying time, and the formation of analyte concentration gradients.
Additionally, cards must be dried horizontally at room temperature for 3–4 hours, away from heat, direct sunlight, and humidity. Improper drying creates “chromatographic effects,” where analytes migrate to the edges of the spot, producing serum rings or super-saturated centers. Cards showing clotting, hemolysis, or serum rings must be rejected because the analyte is no longer homogeneously distributed.
The Internal Standard Dilemma
How you introduce the internal standard (IS) fundamentally impacts accuracy. You cannot simply spike IS into whole blood before spotting and assume it will mimic the analyte’s distribution.
IS added to liquid blood may behave differently than analyte that is bound to cellular components or proteins during drying. If you extract a sub-punch from a spot where IS and analyte are not identically distributed, you lose the compensatory power of the internal standard. Common strategies include pre-impregnating the card with IS or adding IS to the extraction solvent, each with its own recovery and matrix-effect trade-offs.
Sub-Punch Homogeneity and Extract Carryover
When taking a partial sub-punch rather than extracting the entire spot, you must demonstrate that the analyte is uniformly distributed across the spot. Hematocrit variation and incomplete drying can create a non-uniform spatial distribution, making sub-punching unreliable.
Extract carryover is another parameter that often gets overlooked. DBS cards contain additives, residual detergents, or paper binder chemistries that can interfere with MS ionization or chromatography. You must validate that the extraction process does not introduce systematic matrix interference that varies between card lots.
Card Substrate and Storage Stability
The card itself is a variable. Properties such as paper thickness, density, and whether the paper is untreated or chemically treated influence extraction recovery, matrix background, and chromatographic behavior.
For long-term storage, stability must be demonstrated under controlled conditions. Sealed, low-gas-permeable bags with desiccant maintaining humidity below 30% are required to prevent analyte degradation. Temperature excursions during transport must be simulated in the validation to reflect real-world sample journey.
How Capillary Plasma Microsampling Overcomes These Limitations
Capillary microsampling addresses the root cause of DBS variability: the whole-blood matrix itself. By separating plasma from red blood cells before drying, you eliminate the variables that are most difficult to control.
The Dried Plasma Spot Principle
The workflow is elegantly straightforward. Blood is collected into an EDTA-coated capillary tube fitted with a thixotropic gel plug. Centrifugation of the capillary directly separates plasma from cells, with the gel forming a physical barrier between the two phases.
The isolated plasma is then dispensed from the capillary onto a collection card, creating a dried plasma spot (DPS). This retains all the logistical advantages of micro-volume dry sampling—small volume, ambient transport, simplified logistics—while converting the sample into a far more consistent matrix.
Eliminating Hematocrit-Induced Bias
Because the blood cells are removed, the hematocrit concentration of the original sample no longer influences spot formation, spot size, or analyte distribution. The volume of plasma dispensed is controlled by the capillary geometry and the gel barrier, not by the viscosity of whole blood.
This directly removes the most significant source of area bias in DBS. You no longer need to measure hematocrit to correct quantitation, and sub-punch homogeneity becomes far more predictable because you are sampling a simple, cell-free matrix.
Improved Homogeneity and Internal Standard Behavior
Plasma spots dry more uniformly than whole-blood spots, because the absence of cells eliminates the differential migration of analytes between the cellular and fluid phases. The internal standard can be introduced into liquid plasma prior to drying, where it will distribute in a manner that much more closely mirrors the analyte’s behavior.
Extract carryover from card chemicals remains, but the matrix interference from cellular components, hemolysis, and hemoglobin-derived ion suppression is greatly diminished.
Understanding the Trade-offs
Capillary plasma microsampling is not a flawless replacement; it introduces its own set of considerations.
The collection device contains a thixotropic gel. You must validate that the gel does not adsorb your analyte of interest or introduce leachable contaminants that cause matrix effects.
Centrifugation is now mandatory. This moves sample processing from a simple “drop blood, dry, ship” paradigm to one requiring a small centrifuge at the collection site. That can be a barrier for remote, low-resource settings.
The sample is no longer a whole-blood sample. If your assay requires measurement of an analyte that is heavily partitioned into red blood cells, a plasma spot will underestimate the total blood concentration. In such cases, DPS simply will not work, and you must return to whole-blood DBS and invest heavily in hematocrit correction strategies.
Making the Right Choice for Your Assay
The decision between DBS and capillary plasma microsampling depends on the analyte’s biology and the collection environment. Here is how to navigate that choice.
- If your primary focus is an analyte that is evenly distributed between plasma and red cells, and you can tightly control hematocrit: Traditional DBS with whole-spot extraction and stringent donor hematocrit criteria may be acceptable.
- If your primary focus is an analyte that is strictly plasma-based, and you cannot control hematocrit in your population: Capillary plasma microsampling (DPS) is the superior approach, as it eliminates the single largest source of quantitative bias.
- If your primary focus is simplifying collection in remote field sites with no power: DBS remains operationally simpler, but you must build an extremely robust validation that includes a hematocrit correction model and rejects non-homogeneous spots.
- If your primary focus is the highest possible accuracy and precision in a regulated bioanalytical lab: DPS offers a cleaner matrix, better IS behavior, and greater sub-punch reliability, provided you have the infrastructure for sample centrifugation.
Select the sampling format that aligns best with your analyte’s distribution and the practical constraints of your collection environment—or validate both and make the choice based on the data.
Summary Table:
| Analytical Parameter | Traditional DBS Challenge | Capillary Plasma Microsampling (DPS) Solution |
|---|---|---|
| Hematocrit (HCT) Bias | HCT alters blood viscosity & spot spread, causing volume and area bias. | Pre-separation removes red cells, eliminating HCT-dependent area bias. |
| Spot Homogeneity | Differential drying causes chromatographic rings & analyte concentration gradients. | Cell-free plasma dries uniformly without cellular migration artifacts. |
| Internal Standard (IS) | IS added to extraction may not mirror analyte bound to blood components. | IS added to liquid plasma distributes identically to plasma-bound analytes. |
| Matrix Interference | Hemolysis and cellular lysates cause ionization suppression in LC-MS/MS. | Gel separation provides cleaner plasma matrix with minimal background interference. |
Accelerate Your Assay Validation from Concept to Clinic
Navigating matrix effects, sample homogeneity, and microsampling protocols requires robust reagents and technical expertise. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you are developing traditional DBS workflows or transitioning to capillary plasma microsampling, we deliver the quality raw materials and expert guidance needed to ensure assay accuracy.
Contact CamelBio Today to partner with our technical experts and elevate your bioanalytical assay development!